Davide Bedognetti

List of Publications by Year
in descending order

119 papers	10,458 citations	61984 43 h-index	39675 94 g-index
131 all docs	131 docs citations	131 times ranked	17725 citing authors

#	Article	IF	Citations
1	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
2	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity, 2013, 39, 11-26.	14.3	700
3	Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. ACS Nano, 2020, 14, 6383-6406.	14.6	455
4	BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature, 2013, 498, 506-510.	27.8	332
5	Evolution of Metastases in Space and Time under Immune Selection. Cell, 2018, 175, 751-765.e16.	28.9	322
6	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in Immunology, 2018, 9, 947.	4.8	261
7	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology, 2018, 7, e1490854.	4.6	200
8	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 2017, 6, e1253654.	4.6	146
9	Functionalized multiwalled carbon nanotubes as ultrasound contrast agents. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16612-16617.	7.1	139
10	CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer, 2013, 109, 2412-2423.	6.4	136
11	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	9.4	124
12	Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. Nature Communications, 2017, 8, 1109.	12.8	111
13	Functionalized carbon nanotubes as immunomodulator systems. Biomaterials, 2013, 34, 4395-4403.	11.4	109
14	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. International Journal of Molecular Sciences, 2017, 18, 2229.	4.1	105
15	Impact of carbon nanotubes and graphene on immune cells. Journal of Translational Medicine, 2014, 12, 138.	4.4	104
16	Photodynamic Therapy Based on Graphene and MXene in Cancer Theranostics. Frontiers in Bioengineering and Biotechnology, 2019, 7, 295.	4.1	100
17	Germline genetic contribution to the immune landscape of cancer. Immunity, 2021, 54, 367-386.e8.	14.3	95
18	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. Journal of Immunology, 2011, 186, 6044-6055.	0.8	93

#	Article	IF	Citations
19	Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors. Advanced Healthcare Materials, 2016, 5, 276-287.	7.6	90
20	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunology Research, 2016, 4, 600-610.	3.4	86
21	Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. Journal of Translational Medicine, 2011, 9, 174.	4.4	85
22	An immunologic portrait of cancer. Journal of Translational Medicine, 2011, 9, 146.	4.4	83
23	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine, 2013, 11, 145.	4.4	82
24	Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics. Theranostics, 2020, 10, 5435-5488.	10.0	80
25	Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444.	2.4	75
26	Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Medical Genomics, 2011, 4, 38.	1.5	73
27	Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer, 2016, 16, 911.	2.6	70
28	Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Scientific Reports, 2016, 6, 26345.	3.3	69
29	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
30	Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Review of Vaccines, 2010, 9, 555-565.	4.4	63
31	2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2. Nano Today, 2021, 38, 101136.	11.9	63
32	IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes. British Journal of Cancer, 2013, 109, 76-82.	6.4	58
33	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
34	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature Cancer, 2020, 1, 1204-1217.	13.2	58
35	Disentangling the relationship between tumor genetic programs and immune responsiveness. Current Opinion in Immunology, 2016, 39, 150-158.	5.5	57
36	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57

#	Article	IF	Citations
37	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research, 2010, 16, 5862-5872.	7.0	56
38	Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. Journal of Clinical Oncology, 2013, 31, 2369-2371.	1.6	56
39	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.	4.6	56
40	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. British Journal of Cancer, 2018, 119, 1383-1391.	6.4	54
41	Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 617281.	3.7	53
42	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research, 2015, 21, 2840-2850.	7.0	52
43	HLA-G: A New Immune Checkpoint in Cancer?. International Journal of Molecular Sciences, 2020, 21, 4528.	4.1	52
44	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Experimental Hematology, 2010, 38, 979-988.	0.4	48
45	Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115.	1.4	45
46	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences, 2017, 1, 429-445.	2.6	45
47	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunology, 2017, 6, e1323618.	4.6	42
48	How can nanotechnology help the fight against breast cancer?. Nanoscale, 2018, 10, 11719-11731.	5.6	42
49	Melanoma NOS1 expression promotes dysfunctional IFN signaling. Journal of Clinical Investigation, 2014, 124, 2147-2159.	8.2	40
50	IRF5 gene polymorphisms in melanoma. Journal of Translational Medicine, 2012, 10, 170.	4.4	36
51	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572.	3.3	36
52	An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients. European Urology, 2010, 57, 238-245.	1.9	35
53	The perception of nanotechnology and nanomedicine: a worldwide social media study. Nanomedicine, 2014, 9, 1475-1486.	3.3	34
54	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Frontiers in Immunology, 2019, 10, 2410.	4.8	33

#	Article	IF	Citations
55	Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. Immunology, 2020, 161, 291-302.	4.4	32
56	A map of tumor–host interactions in glioma at single-cell resolution. GigaScience, 2020, 9, .	6.4	32
57	The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics, 2012, 13, 156.	2.8	29
58	Graphene, other carbon nanomaterials and the immune system: toward nanoimmunity-by-design. JPhys Materials, 2020, 3, 034009.	4.2	29
59	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
60	The immune–related role of BRAF in melanoma. Molecular Oncology, 2015, 9, 93-104.	4.6	28
61	Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2733-2733.	1.4	28
62	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. Journal of the National Cancer Institute, 2011, 103, 1529-1539.	6.3	27
63	Impact of the surface functionalization on nanodiamond biocompatibility: a comprehensive view on human blood immune cells. Carbon, 2020, 160, 390-404.	10.3	27
64	SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. Journal of Translational Medicine, 2011, 9, 155.	4.4	25
65	Definition of erythroid cell–positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection. Clinical and Translational Medicine, 2020, 10, e244.	4.0	22
66	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer, 2011, 11, 451.	2.6	20
67	Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. Breast Cancer Research and Treatment, 2019, 177, 335-343.	2.5	19
68	A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis. Frontiers in Immunology, 2020, 11, 587946.	4.8	19
69	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	8.6	19
70	BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R. Bioinformatics, 2021, 37, 2382-2389.	4.1	18
71	Common pathways to tumor rejection. Annals of the New York Academy of Sciences, 2013, 1284, 75-79.	3.8	17
72	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy, 2014, 14, 663-686.	3.1	17

#	Article	IF	Citations
73	Seasonal and pandemic (A/H1N1 2009) MF-59â€"adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood, 2012, 120, 1954-1957.	1.4	16
74	Direct T cellâ€"tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme. British Journal of Cancer, 2014, 110, 2955-2964.	6.4	16
75	Sterol synthesis pathway inhibition as a target for cancer treatment. Cancer Letters, 2020, 493, 19-30.	7.2	15
76	Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. Molecular Immunology, 2020, 128, 205-218.	2.2	15
77	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
78	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	1.6	14
79	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight, 2021, 6, .	5.0	14
80	Prospective validation study of prognostic biomarkers to predict adverse outcomes in patients with COVID-19: a study protocol. BMJ Open, 2021, 11, e044497.	1.9	14
81	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296.	1.6	14
82	Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study. Lancet Oncology, The, 2022, 23, 341-352.	10.7	14
83	Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications. Frontiers in Oncology, 2019, 9, 1328.	2.8	13
84	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. British Journal of Cancer, 2021, 124, 760-769.	6.4	13
85	The immune landscape of solid pediatric tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	13
86	Meta-analysis and metagenes. OncoImmunology, 2014, 3, e28727.	4.6	12
87	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. Npj Breast Cancer, 2021, 7, 10.	5.2	11
88	miRNAs as novel immunoregulators in cancer. Seminars in Cell and Developmental Biology, 2022, 124, 3-14.	5.0	11
89	Network-based identification of key master regulators associated with an immune-silent cancer phenotype. Briefings in Bioinformatics, 2021, 22, .	6.5	11
90	Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Medical Oncology, 2012, 29, 3456-3461.	2.5	10

#	Article	IF	Citations
91	Toward High‐Dimensional Single‐Cell Analysis of Graphene Oxide Biological Impact: Tracking on Immune Cells by Single‐Cell Mass Cytometry. Small, 2020, 16, 2000123.	10.0	10
92	Graphene oxide activates B cells with upregulation of granzyme B expression: evidence at the single-cell level for its immune-modulatory properties and anticancer activity. Nanoscale, 2022, 14, 333-349.	5.6	9
93	Inherent transcriptional signatures of NK cells are associated with response to IFNÎ±â€‰+â€‰rivabirin therapy in patients with Hepatitis C Virus. Journal of Translational Medicine, 2015, 13, 77.	4.4	8
94	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	3.0	8
95	Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes. Frontiers in Oncology, 2021, 11, 734959.	2.8	8
96	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. Pituitary, 2012, 15, 209-214.	2.9	7
97	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. Journal of Translational Medicine, 2020, 18, 192.	4.4	7
98	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. American Journal of Pathology, 2021, 191, 1774-1786.	3.8	7
99	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. International Journal of Hematology, 2010, 91, 342-344.	1.6	6
100	Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations. Journal of Translational Medicine, 2016, 14, 22.	4.4	6
101	The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. Cancer Treatment and Research, 2020, 180, 149-172.	0.5	5
102	Toward the identification of genetic determinants of breast cancer immune responsiveness. , 2015, 3, P1.		4
103	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 99-127.	0.4	4
104	A Multi-layer Molecular Fresco of the Immune Diversity across Hematologic Malignancies. Cancer Cell, 2020, 38, 313-316.	16.8	4
105	STXBP6, reciprocally regulated with autophagy, reduces triple negative breast cancer aggressiveness. Clinical and Translational Medicine, 2020, 10, e147.	4.0	3
106	Single‐Cell Analysis: Toward High‐Dimensional Single‐Cell Analysis of Graphene Oxide Biological Impact: Tracking on Immune Cells by Single‐Cell Mass Cytometry (Small 21/2020). Small, 2020, 16, 2070117.	10.0	3
107	Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine, 2021, 11, e434.	4.0	3
108	Molecular Profiling of Immunotherapeutic Resistance. , 2013, , 373-394.		2

#	Article	IF	Citations
109	Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer. , 2014, 2, .		2
110	Monoallelic expression in melanoma. Journal of Translational Medicine, 2019, 17, 112.	4.4	2
111	Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8576-8576.	1.6	2
112	Gynaecomastia: The Anastrozole Paradox. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 205-6.	0.9	1
113	Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells.. Blood, 2009, 114, 936-936.	1.4	1
114	The immune-related role of BRAF in melanoma. Journal of Translational Medicine, 2015, 13, K19.	4.4	0
115	Signatures Associated with Acute Rejection: Allograft Rejection. , 2011, , 305-345.		0
116	The Immune-related Role Of Braf In Melanoma. , 2014, , .		0
117	Effects Of Rituximab On The Response To Influenza Vaccine In Complete Remission Lymphoma Patients. , 2014, , .		0
118	Defining genetic modulators of intratumoral immune response in breast cancer through a system biology approach. , 2016, , .		0
119	Functional Genome Profiling to Understand Cancer Immune Responsiveness. Methods in Molecular Biology, 2020, 2055, 231-244.	0.9	0